Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
CDMC 2018: Shifting gears in the management of diabetes and CVD
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
- Dr. Adie Viljoen, MD
Lecture: The GLP1 landscape - refining our understanding
Lecture: The GLP1 landscape - refining our understanding
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: The GLP1 landscape - refining our understanding
Lecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
Lecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
- Prof. Richard Hobbs, MD
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
- Prof. Eduard Montanya Barcelona